Incidence and severity of immune-related hepatitis after dual checkpoint therapy is linked to younger age independent of herpes virus immunity.
Age
Checkpoint therapy
Hepatitis
Herpes virus
Immune-related adverse effects
Journal
Journal of translational medicine
ISSN: 1479-5876
Titre abrégé: J Transl Med
Pays: England
ID NLM: 101190741
Informations de publication
Date de publication:
12 Dec 2022
12 Dec 2022
Historique:
received:
06
10
2022
accepted:
04
11
2022
entrez:
12
12
2022
pubmed:
13
12
2022
medline:
15
12
2022
Statut:
epublish
Résumé
Dual immune checkpoint blockade (ICB) therapy can result in immune-related-adverse events (irAE) such as ICB-hepatitis. An expansion of effector-memory (TEM) CD4 T cells associated with antiviral immunity against herpesviridae was implicated in ICB-hepatitis. Notably, these memory subsets are frequently associated with age. Here, we sought to understand baseline patient, immune and viral biomarkers associated with the development of ICB-hepatitis to identify currently lacking baseline predictors and test if an expansion of TEM or positive serology against herpesviridae can predict ICB-hepatitis. A discovery (n = 39) and validation cohort (n = 67) of patients with advanced melanoma undergoing anti-PD-1&anti-CTLA4 combination therapy (total n = 106) were analyzed for baseline clinical characteristics, occurrence of irAE and oncological outcomes alongside serological status for CMV, EBV and HSV. Immune populations were profiled by high-parametric flow cytometry (n = 29). ICB-hepatitis occurred in 59% of patients within 100 days; 35.9% developed severe (CTCAE 3-4) hepatitis. Incidence of ICB-hepatitis was higher in the younger (< 55y: 85.7%) compared to older (> = 55y: 27.8%) age group (p = 0.0003), occured earlier in younger patients (p < 0.0001). The association of younger age with ICB-Hepatitis was also observed in the validation cohort (p = 0.0486). Incidence of ICB-hepatitis was also associated with additional non-hepatic irAE (p = 0.018), but neither positive IgG serostatus for CMV, EBV or HSV nor TEM subsets despite an association of T cell subsets with age. Younger age more accurately predicts ICB-hepatitis after anti-PD-1&anti-CTLA4 checkpoint therapy at baseline compared to herpes virus serology or TEM subsets. Younger patients should be carefully monitored for the development of ICB-hepatitis.
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
Dual immune checkpoint blockade (ICB) therapy can result in immune-related-adverse events (irAE) such as ICB-hepatitis. An expansion of effector-memory (TEM) CD4 T cells associated with antiviral immunity against herpesviridae was implicated in ICB-hepatitis. Notably, these memory subsets are frequently associated with age. Here, we sought to understand baseline patient, immune and viral biomarkers associated with the development of ICB-hepatitis to identify currently lacking baseline predictors and test if an expansion of TEM or positive serology against herpesviridae can predict ICB-hepatitis.
METHODS
METHODS
A discovery (n = 39) and validation cohort (n = 67) of patients with advanced melanoma undergoing anti-PD-1&anti-CTLA4 combination therapy (total n = 106) were analyzed for baseline clinical characteristics, occurrence of irAE and oncological outcomes alongside serological status for CMV, EBV and HSV. Immune populations were profiled by high-parametric flow cytometry (n = 29).
RESULTS
RESULTS
ICB-hepatitis occurred in 59% of patients within 100 days; 35.9% developed severe (CTCAE 3-4) hepatitis. Incidence of ICB-hepatitis was higher in the younger (< 55y: 85.7%) compared to older (> = 55y: 27.8%) age group (p = 0.0003), occured earlier in younger patients (p < 0.0001). The association of younger age with ICB-Hepatitis was also observed in the validation cohort (p = 0.0486). Incidence of ICB-hepatitis was also associated with additional non-hepatic irAE (p = 0.018), but neither positive IgG serostatus for CMV, EBV or HSV nor TEM subsets despite an association of T cell subsets with age.
CONCLUSION
CONCLUSIONS
Younger age more accurately predicts ICB-hepatitis after anti-PD-1&anti-CTLA4 checkpoint therapy at baseline compared to herpes virus serology or TEM subsets. Younger patients should be carefully monitored for the development of ICB-hepatitis.
Identifiants
pubmed: 36503532
doi: 10.1186/s12967-022-03755-3
pii: 10.1186/s12967-022-03755-3
pmc: PMC9743538
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
582Subventions
Organisme : DFG
ID : 256073931
Organisme : DFG
ID : 441891347
Organisme : DFG
ID : 413517907
Organisme : DFG
ID : 378189018
Informations de copyright
© 2022. The Author(s).
Références
Nat Med. 2019 Aug;25(8):1243-1250
pubmed: 31332390
Cancers (Basel). 2020 Aug 18;12(8):
pubmed: 32824780
Immunology. 2020 Feb;159(2):167-177
pubmed: 31646612
J Clin Oncol. 2017 Dec 1;35(34):3807-3814
pubmed: 28841387
Nat Med. 2022 Feb;28(2):353-362
pubmed: 35027754
Exp Mol Med. 2019 Dec 11;51(12):1-9
pubmed: 31827070
Cell. 2020 Aug 6;182(3):655-671.e22
pubmed: 32603654
Gastroenterology. 2002 Oct;123(4):1252-64
pubmed: 12360486
Immun Ageing. 2017 May 10;14:10
pubmed: 28491117
Immun Ageing. 2015 Dec 04;12:25
pubmed: 26640505
Nat Commun. 2021 Mar 4;12(1):1439
pubmed: 33664251
Lancet. 2021 Jan 30;397(10272):375-386
pubmed: 33485464
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv264-iv266
pubmed: 29917046
Lancet Oncol. 2016 Nov;17(11):1558-1568
pubmed: 27622997
N Engl J Med. 2018 May 31;378(22):2093-2104
pubmed: 29658845
N Engl J Med. 2019 Oct 17;381(16):1535-1546
pubmed: 31562797
J Hepatol. 2021 Jul;75(1):177-189
pubmed: 33631227
N Engl J Med. 2015 Jul 2;373(1):23-34
pubmed: 26027431
J Exp Med. 2017 Mar 6;214(3):651-667
pubmed: 28130404
Immun Ageing. 2021 Jan 18;18(1):5
pubmed: 33461563